Ibogaine Cardiac Risks: QT Prolongation, Deaths & Safety Protocols

This page presents the most complete, citation-backed analysis of ibogaine's cardiac risks available anywhere. We believe that honest safety information — not fear or minimization — empowers patients to make informed decisions and demand proper medical protocols.

Understanding QT Prolongation

What Is the QT Interval?

The QT interval is a measurement on an electrocardiogram (ECG/EKG) representing the time it takes for your heart's ventricles to electrically depolarize (contract) and repolarize (reset). It's measured in milliseconds (ms) and corrected for heart rate as QTc.

What the Research Shows About Ibogaine and QTc

The most rigorous prospective study of ibogaine's cardiac effects was conducted by Knuijver et al. (2022) in the Netherlands, published in Addiction. In 14 opioid-dependent patients treated with ibogaine under medical supervision:

• Baseline QTc median: 411ms (range 387-434ms)
• Mean QTc prolongation: 95ms (range 29-146ms)
• 50% of subjects exceeded QTc 500ms — the widely accepted danger threshold
• 43% still had QTc >450ms after 24 hours — due to noribogaine's long half-life
• No Torsades de Pointes occurred — but only because patients were under continuous cardiac monitoring

Other case reports have documented even more extreme prolongation. A case published by Henstra et al. (2017) in Clinical Toxicology documented a QTc of 647ms with multiple arrhythmias including actual Torsades de Pointes — and QT prolongation that persisted for 12 days after a single dose. Steinberg & Deyell (2018) reported a case requiring defibrillation for ventricular flutter, with QT normalization taking 7 days.

How Ibogaine Affects the Heart: hERG Channel Blockade

The molecular mechanism behind ibogaine's cardiac danger was established by a series of landmark studies from the Medical University of Vienna.

The hERG Potassium Channel

The hERG (human Ether-a-go-go-Related Gene) potassium channel is critical for normal heart rhythm. It controls the rapid delayed rectifier potassium current (IKr) that helps the heart's ventricles repolarize after each beat. When this channel is blocked, the heart takes longer to reset — prolonging the QT interval.

Koenig et al. (2012), published in Cardiovascular Research, first quantified ibogaine's hERG blocking potency:

• Ibogaine IC50 for hERG: 3.9 ± 0.3 micromolar — this overlaps directly with therapeutic plasma concentrations
• Ibogaine blocks hERG at the exact concentrations used for addiction treatment

Thurner et al. (2014) in the Journal of Pharmacology and Experimental Therapeutics further clarified that ibogaine blocks hERG from the cytosolic side, preferentially binding to the open and inactivated states of the channel — meaning the block worsens as the heart beats.

Koenig et al. (2013) expanded the picture, showing ibogaine also inhibits Nav1.5 (sodium) and Cav1.2 (calcium) cardiac channels. In computer models of human cardiac cells, the net effect is QT prolongation at therapeutic concentrations.

The Noribogaine Factor: Why Cardiac Risk Persists for Days

One of the most critical — and underappreciated — cardiac risks of ibogaine is its primary metabolite, noribogaine. Research has shown that noribogaine is more dangerous to the heart than ibogaine itself.

Alper et al. (2016), published in Cardiovascular Toxicology, measured hERG blocking potency across iboga alkaloids:

Rubi et al. (2017) in Cardiovascular Toxicology confirmed this in human heart cells (iPSC-derived cardiomyocytes), concluding: "Because of its long half-life in human plasma, we consider noribogaine, rather than ibogaine itself, as the crucial molecule triggering this sequence of deleterious events."

The only randomized, double-blind, placebo-controlled trial of noribogaine's cardiac effects (Glue et al., 2016, Clinical Pharmacology in Drug Development) demonstrated dose-dependent QTc prolongation: 16ms at 60mg, 28ms at 120mg, and 42ms at 180mg — with a linear relationship of 0.17ms per ng/mL of plasma concentration.

Documented Fatalities: What the Data Shows

We believe patients deserve honest, complete information about ibogaine's risks. Here is what the published medical literature documents.

Published Fatality Data

Context for These Numbers

The fatality data tells an important story when examined carefully:

• Most deaths occurred in underground, unsupervised settings — with no cardiac screening, no monitoring, and often with co-ingested drugs
• Pre-existing cardiac conditions were undetected in many cases — the individuals would likely have been screened out by any responsible clinic
• Drug interactions (especially methadone, which independently prolongs QT) contributed to multiple deaths
• In medically supervised settings with proper protocols, serious cardiac events are rare — but not zero
• For context, untreated opioid addiction carries a 1-3% annual mortality rate. For many patients, ibogaine's risk profile compares favorably to continued addiction

Who Is at Greatest Cardiac Risk?

Additional Risk Factors Requiring Extra Caution

• Long-term opioid use: Chronic opioid use can cause cardiac remodeling and QT prolongation
• Stimulant abuse history: Cocaine and methamphetamine cause direct cardiac damage — echocardiogram required
• Age over 60: Higher baseline cardiac risk, slower drug metabolism
• Hypokalemia or hypomagnesemia: Common in people with substance use disorders; must be corrected before treatment
• Eating disorders: Electrolyte derangements increase arrhythmia risk
• Family history of sudden cardiac death: May indicate undiagnosed channelopathy

Drug Interactions That Increase Cardiac Risk

Several drug categories compound ibogaine's cardiac risks. These have been implicated in fatality cases documented in the literature:

For a full medication interaction database, see our Medication Interactions Guide and Interactive Medication Checker Tool.

Cardiac Screening: What Safe Clinics Require

The difference between ibogaine being administered safely versus dangerously often comes down to the quality of pre-treatment cardiac screening.

Cardiac Monitoring During Treatment

Given that 50% of patients exceed the dangerous QTc threshold of 500ms, continuous cardiac monitoring is the single most important safety measure during ibogaine treatment.

Essential Monitoring Protocol

• Continuous ECG telemetry — 3-lead minimum, ideally 5-12 lead, for the entire treatment and 24-48 hours post-dose
• QTc measurement every 2-4 hours — document the trajectory, not just a single reading
• Pulse oximetry — continuous oxygen saturation monitoring
• Blood pressure checks — every 30-60 minutes during peak ibogaine effects
• Electrolyte monitoring — repeat potassium and magnesium levels during treatment

Emergency Equipment Required On-Site

• Automated external defibrillator (AED) — or manual defibrillator with trained staff
• Crash cart — with IV access supplies and emergency medications
• IV magnesium sulfate — first-line treatment for Torsades de Pointes
• Isoproterenol — for refractory TdP (increases heart rate to shorten QT)
• Temporary pacing capability — overdrive pacing for sustained TdP

How Safe Clinics Reduce Cardiac Risk

The Stanford MISTIC Protocol

The most significant recent safety data comes from Stanford University's MISTIC study (Cherian et al., Nature Medicine, 2024). In 30 Special Operations Forces veterans with traumatic brain injuries treated with magnesium-ibogaine combination therapy:

• Zero unexpected or serious adverse events
• 88% reduction in PTSD symptoms
• 87% reduction in depression
• 81% reduction in anxiety

While this study focused on TBI/PTSD rather than addiction, its safety data is significant because it demonstrates that co-administration of magnesium with ibogaine, combined with proper medical protocols, can substantially mitigate cardiac risk.

Key Risk Mitigation Strategies

1. Magnesium supplementation: IV magnesium sulfate before and during treatment stabilizes cardiac repolarization, reducing TdP risk even with prolonged QT
2. Electrolyte optimization: Correct potassium (target 4.5-5.5 mEq/L) and magnesium (target 1.5-2.5 mEq/L) days before treatment, not just at dosing
3. Test dosing: A small initial dose (50-100mg) allows assessment of individual cardiac response before the full dose
4. Divided dosing: Multiple smaller doses reduce peak QT prolongation compared to a single flood dose
5. Extended monitoring: Given that 43% of patients still had elevated QTc at 24 hours, monitoring should continue for at least 48-72 hours
6. Hydration protocol: Electrolyte-containing fluids (not just water) maintained throughout treatment

Clinical Settings vs. Underground: The Safety Gap

No single study directly compares mortality rates between supervised and unsupervised ibogaine use. However, the published evidence collectively tells a clear story:

Important caveat: Even in the Knuijver study's supervised setting, 50% of patients exceeded QTc 500ms. These patients survived because they were being monitored — not because the cardiac risk was absent. Medical supervision doesn't eliminate the risk; it provides the ability to detect and respond to cardiac emergencies.

Questions to Ask Your Clinic About Cardiac Safety

Use these evidence-based questions to evaluate any ibogaine clinic's cardiac safety protocols. A clinic that cannot answer these confidently is not adequately prepared.

1. Do you perform 12-lead ECGs before treatment? (Not just rhythm strips — need full QTc measurement)
2. What is your QTc cutoff for exclusion? (Should be <450ms for men, <470ms for women)
3. Do you check electrolyte levels? (Potassium, magnesium, calcium — must be corrected before dosing)
4. What cardiac monitoring do you use during treatment? (Continuous ECG telemetry — not periodic spot checks)
5. How often do you measure QTc during treatment? (Every 2-4 hours minimum)
6. Do you administer IV magnesium? (Prophylactic magnesium reduces TdP risk)
7. Do you have a defibrillator on-site? (Essential — not optional)
8. Who monitors patients — physician, nurse, or non-medical staff? (Medical credentials matter)
9. How long do you monitor after the dose? (Minimum 24 hours; 48-72 is safer given noribogaine persistence)
10. Do you use test dosing? (Smaller initial dose to assess cardiac response)
11. What is your transfer protocol to the nearest hospital? (Distance, transport time, pre-arranged agreements)
12. Have you had any adverse cardiac events? (Honest clinics disclose — no clinic with significant volume has had zero events)

Comprehensive Drug Interaction Table

The following table expands beyond the basic categories to include specific drugs most commonly encountered in ibogaine candidate populations — many of which have been implicated in reported adverse events.

This table covers the most commonly encountered interactions. For a complete medication database searchable by drug name, use our Interactive Medication Checker Tool.

Female-Specific Cardiac Considerations

Ibogaine's cardiac risks are not uniform across all patients. Biological sex is a significant modifier of QT prolongation risk, with important clinical implications for women seeking ibogaine treatment.

Why Women Face Higher QT Prolongation Risk

Women have a naturally longer baseline QTc interval than men — typically 10-20ms longer, attributed to the influence of sex hormones on cardiac ion channels. Estrogen promotes hERG channel function while progesterone and androgens modulate it differently across the menstrual cycle. This physiological difference has significant clinical consequences:

• Lower QTc cutoff for women: The absolute contraindication threshold for ibogaine treatment is QTc >470ms for women vs. 450ms for men — reflecting baseline sex differences. However, since women's baseline QTc is already higher, their relative margin before reaching dangerous prolongation is smaller.
• Higher incidence of drug-induced TdP: Women account for approximately 70% of all drug-induced Torsades de Pointes cases across all drug classes. For ibogaine specifically, this data is not sex-stratified in published literature, but the general finding strongly suggests elevated sex-based risk.
• Hormonal cycle fluctuations: QTc varies across the menstrual cycle, with the longest intervals occurring in the luteal phase (after ovulation). Ideally, ibogaine pre-screening ECG should be performed in the early follicular phase to avoid cycle-related prolongation confounding the baseline measurement.
• Oral contraceptives: Certain oral contraceptives have been associated with modest QT prolongation in some studies. Women on OCP should disclose this to their clinic's medical team for risk stratification.
• Eating disorder history: Disordered eating is more prevalent in women and significantly increases QT risk through electrolyte derangements (hypokalemia, hypomagnesemia). Women with any history of eating disorders require particularly thorough electrolyte assessment before treatment.

CYP2D6 Polymorphisms: Race-Specific Metabolism Differences

Ibogaine is primarily metabolized by the liver enzyme CYP2D6 (cytochrome P450 2D6), which converts ibogaine to its active metabolite noribogaine. The gene encoding CYP2D6 is highly polymorphic — individuals can carry variant alleles that make them dramatically slower or faster ibogaine metabolizers. This is one of the most clinically significant and underappreciated cardiac risk factors in ibogaine treatment.

The Four CYP2D6 Phenotypes

Race and Ethnicity Considerations

CYP2D6 allele frequencies vary substantially across ethnic groups, creating population-level differences in ibogaine metabolism risk. This is not about race as a social construct but about the documented population genetics of CYP2D6 polymorphism distribution:

• Caucasians (European ancestry): Highest frequency of CYP2D6 poor metabolizer alleles (*3, *4, *5, *6), with 5-10% being poor metabolizers. This population also has the highest frequency of ultra-rapid metabolizers via gene duplication.
• East Asian populations (Chinese, Japanese, Korean): Very low poor metabolizer frequency (1-2%) but significantly higher rates of the *10 intermediate allele (50%+ frequency) — meaning a larger proportion of East Asians are intermediate metabolizers requiring dose consideration.
• Sub-Saharan African populations: Low poor metabolizer frequency but notable frequency of the *17 allele, which causes intermediate-to-poor metabolism in a subset. African ancestry populations have the most complex CYP2D6 allele distribution.
• Hispanic populations: Intermediate metabolizer rates are lower than Caucasians; poor metabolizer frequency is approximately 3-5%.
• Middle Eastern and North African populations: Elevated ultra-rapid metabolizer rates (some studies report 20-29% in certain North African groups via gene duplication alleles).

Pre-Screening Cardiac Protocol Checklist

This checklist represents the comprehensive pre-treatment cardiac evaluation that every responsible ibogaine clinic should complete before administering any dose. Use it to evaluate clinics you're considering and to prepare for your own screening process.

Frequently Asked Questions

References